601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

Detailed Description
-----------------
Following a 14-day maximum screening period, patients will be randomized and followed for approximately 36 weeks. Treatment visits will be scheduled in 4-week intervals. After 1 initial injection of 601 or ranibizumab (loading phase), subjects will enter an individualized flexible treatment (IFT) phase (week 4 to week 32). During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an injection or not. Safety and efficacy outcomes will continue to be evaluated up to a period of 36 weeks unless the patient is withdrawn or discontinues the study.

Official Title
-----------------
A Randomized, Double Masked, Multicenter, Phase II Study Assessing the Safety and Efficacy of 601 Versus Ranibizumab in Patients With Visual Impairment Due to Pathological Myopic Choroidal Neovascularization (pmCNV)

Conditions
-----------------
Pathological Myopic Choroidal Neovascularization

Intervention / Treatment
-----------------
* Drug: 601
* Drug: Ranibizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sign informed consent form and willing to be visited at the time specified in the trial Male or Female, at least 18 years of age The study eye must meet the following criteria Diagnosed with active choroidal neovascularization secondary to pathological myopia BCVA score between 78 and 24 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/320) No optometric media opacity and pupil abnormal BCVA score ≥ 34 letters in the fellow eye, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/200) Exclusion Criteria: CNV secondary to other causes (except pathological myopia), such as neovascularage-related macular degeneration (nAMD), polypoid choroidal vascular disease (PCV), and secondary injury The fovea has fibrosis and organochemical foci or scar or atrophy that obviously involves the fovea and causes irreversible vision loss; Previous use of intraocular or periocular steroids within 3 months prior to baseline, or previous use of dexamethasone intravitreal implant within 6 months prior to enrollment; PDT, Macular laser photocoagulation (focal/grid), vitrectomy or keratoplasty in the study eye at any time prior to baseline. Panretinal laser photocoagulation，YAG laser treatment or any other ocular surgeries (e.g. cataract surgery ) in the study eye within 3 months prior to the baseline Aphakia (except IOL) or posterior capsular defect (except YAG posterior capsulotomy after intraocular lens implantation surgery) For Any Eye: Any eye has active ocular infections (e.g. blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) History of intravitreal use of anti-VEGF drugs (e.g. ranibizumab，bevacizumab，aflibercept, conbercept, etc.) in any eye within 3 months prior to baseline General Exclusion Criteria: History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis History of stroke (cerebrovascular accident), myocardial infarction, active disseminated intravascular coagulation or pronounced bleeding tendency in the past 6 months prior to baseline Diagnosed systemic immune diseases (e.g. ankylosing spondylitis, systemic lupus erythematosus, Behcet's disease, rheumatoid arthritis, scleroderma etc.) any uncontrolled clinical problem (e.g. AIDS, active hepatitis, serious mental, neurological, cardiovascular, respiratory and other systemic diseases or malignant tumors, etc.). Malignant tumors with no metastasis or recurrence within 5 years or cancers in situ cancers are not excluded. History of system use of anti-VEGF drugs (e.g. bevacizumab) within 3 months prior to baseline Laboratory Exclusion Criteria: Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory). Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory) Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normal value for 10 seconds); Other Exclusion Criteria: Non-use of effective contraception during childbearing age (except for women with spontaneous admonishment of more than 12 months) Pregnancy and lactation women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group I<br>601 1.25mg | Drug: 601<br>* intravitreal recombinant humanized anti-VEGF monoclonal antibody<br>|
| Active Comparator: group II<br>Ranibizuman 0.5 mg | Drug: Ranibizumab<br>* intravitreal recombinant humanized anti-VEGF monoclonal antibody<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in best-corrected visual acuity (BCVA) at Week 12 | Assessed with ETDRS visual acuity testing charts. | Baseline to Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Change of BCVA on each visit compared to baseline. | Assessed with ETDRS visual acuity testing charts. | Baseline to Week 36 | 
| Change from baseline in central retina thickness (CRT) on each visit | OCT (optical coherence tomography) was used to assess central retina thickness (CRT) representing the average retinal thickness of the central 1 mm diameter subfield around the foveal center. | Baseline to Week 36 | 
| Proportion of study eyes with a gain ≥ 5, 10 and 15 letters in BCVA on each visit compared to baseline | Assessed with ETDRS visual acuity testing charts. | Baseline to Week 36 | 
| Number of injections from Week 4 to Week 36 | Number of administered injections | Week 4 to Week 36 | 
| Incidence of ocular and non-ocular AEs up to Week 36 | Incidence of ocular and non-ocular AEs | Baseline to Week 36 | 
| Blood concentrations of 601 | Steady-state blood concentrations of 601 | Baseline, Week 4, Week 12, Week 24 and Week 36. | 
| Blood concentrations of VEGF | Detection of VEGF blood concentration | Baseline, Week 4, Week 12, Week 24 and Week 36. | 
| Immunogenicity of 601 | Detection of blood Anti-drug antibody (ADA) status. If ADA was positive, Neutralization antibody (Nab) will be tested | Baseline, Week 4, Week 12, Week 24 and Week 36. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VEGF; pmCNV; antibody